Should You Follow Directors Buying At WM Morrison Supermarkets PLC, Imperial Brands PLC And Hikma Pharmaceuticals Plc?

Is it time to pile into WM Morrison Supermarkets PLC (LON:MRW), Imperial Brands PLC (LON:IMB) and Hikma Pharmaceuticals Plc (LON:HIK) as directors buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Directors have been splashing the cash at Morrisons (LSE: MRW), Imperial Brands (LSE: IMB) and Hikma Pharmaceuticals (LSE: HIK). Should you follow their lead and load up on shares of these three companies?

Morrisons

As expected, annual results from Morrisons on 10 March weren’t great. The UK’s no. 3 supermarket posted a 4% drop in turnover for the year, while underlying earnings fell 28%.

However, there were signs that the turnaround strategy of chief executive David Potts is starting to gain traction. Morrisons said it had achieved its initial aims to begin stabilising like-for-like sales, lowering costs and recruiting new talent. Free cash flow was also ahead of initial expectations, and a big chunk was taken out of net debt.

Coming on top of news a couple of weeks earlier that Morrisons has inked a deal to supply food to Amazon‘s Prime Now and Pantry customers, the company’s prospects are looking more promising than they have for some time.

Mr Potts certainly seems to think so. On Wednesday this week, he splashed out £362,916 on 180,000 shares, paying 201.62p a share. You can buy at a slightly lower price today, and may want to consider doing so, with analysts forecasting a 36% uplift in earnings this year to give an attractive price-to-earnings growth (PEG) ratio of 0.5.

Imperial Brands

Tobacco group Imperial Brands has been enjoying rather better momentum in its business than Morrisons in recent years, and the company said in a trading update in February that it is well placed to meet expectations for its current financial year ending September 2016.

At the same time as David Potts was buying his Morrisons shares on Wednesday, Imperial non-executive director Steven Stanbrook was making his maiden purchase at the tobacco company.

Mr Stanbrook bought 5,000 American Depositary Shares (ADSs) at a bit over $111 a pop, and followed up with a further 3,986 at a similar price, yesterday. One Imperial ADS is equivalent to two ordinary shares, so we’re effectively looking at a 17,972 share purchase at around 3,860p for a total outlay of not much shy of £700,000.

Imperial’s shares are trading nearer 3,800p, as I’m writing, and are on a reasonable forward price-to-earnings (P/E) ratio of 16, with a decent yield of 4.1%, so following Mr Stanbrook’s lead could be a good move.

Hikma Pharmaceuticals

Shares of Hikma Pharmaceuticals have been moving higher since the company released its annual results on 16 March. But the rising price hasn’t put directors off buying.

Non-executive Robert Pickering picked up 2,500 shares at 1,856p a time (total investment, £46,400) on 21 March, followed by a second non-exec, Patrick Butler, who also bagged 2,500 shares, but paid 1,920p (£48,000) on 24 March, before chairman and chief executive Said Darwazah stepped up to the plate yesterday, increasing his interest in the company by 30,000 shares at 1,972p (£591,600).

Hikma, which is focused on the US and Middle East markets, has made substantial investment in R&D and M&A in recent years, the benefits of which are expected to accelerate from 2017. At a current share price of 1,960p, the 2017 P/E is about 17, which looks decent value for a company entering a new growth phase. So, this too could be a stock where it might pay to follow the directors.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Google office headquarters
Investing Articles

1 reason I like buying S&P 500 shares – and 1 reason I don’t

Will this investor try to improve his potential returns by focusing more on S&P 500 shares instead of British ones?…

Read more »

Young woman holding up three fingers
Investing Articles

3 SIPP mistakes to avoid

Our writer explains a trio of potentially costly errors he tries to avoid making when investing his SIPP, on an…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Here’s how (and why) I’d start buying shares with £25 a week

Our writer uses his investment experience and current approach to explain how he would start buying shares on a limited…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s my 5-step approach to earning passive income of £500 a month

Christopher Ruane explains the handful of steps he uses to target hundreds of pounds in passive income each month.

Read more »

Investing Articles

2 UK shares I’ve been buying this week

From a value perspective, UK shares look attractive. But two in particular have been attracting Stephen Wright’s attention over the…

Read more »

Investing Articles

A lifelong second income for just £10 a week? Here’s how!

With a simple, structured approach to buying blue-chip dividend shares at attractive prices, our writer's building a second income for…

Read more »

Investing Articles

Here’s how I’d use a £20k Stocks and Shares ISA to help build generational wealth

Discover how our writer would aim to turn a £20k Stocks and Shares ISA into a sizeable nest egg by…

Read more »